Cargando…

Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation

PURPOSE: SARS-CoV-2 infection may cause varying degrees of cardiac injury and the presence of underlying cardiovascular morbidities contributes to the frequency and severity of occurrence of this complication. Lipodystrophy syndromes are frequently characterized by severe metabolic derangements that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ceccarini, G., Gilio, D., Magno, S., Pelosini, C., Leverone, M., Miceli, C., Barison, A., Fabiani, I., Emdin, M., Santini, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984660/
https://www.ncbi.nlm.nih.gov/pubmed/35384599
http://dx.doi.org/10.1007/s40618-022-01795-6
_version_ 1784682237855268864
author Ceccarini, G.
Gilio, D.
Magno, S.
Pelosini, C.
Leverone, M.
Miceli, C.
Barison, A.
Fabiani, I.
Emdin, M.
Santini, F.
author_facet Ceccarini, G.
Gilio, D.
Magno, S.
Pelosini, C.
Leverone, M.
Miceli, C.
Barison, A.
Fabiani, I.
Emdin, M.
Santini, F.
author_sort Ceccarini, G.
collection PubMed
description PURPOSE: SARS-CoV-2 infection may cause varying degrees of cardiac injury and the presence of underlying cardiovascular morbidities contributes to the frequency and severity of occurrence of this complication. Lipodystrophy syndromes are frequently characterized by severe metabolic derangements that represent relevant cardiovascular risk factors. Besides causing lipodystrophy, mutations in the lamin A/C (LMNA) gene can lead to a wide spectrum of tissue-specific disorders including cardiac involvement. METHODS AND RESULTS: We herein examine the case of two patients affected by atypical progeroid syndrome and partial lipodystrophy due to a heterozygous missense LMNA mutation c.1045 C > T (p.R349W) who presented initially with mild COVID-19 and developed severe cardiovascular complications within few weeks of SARS-CoV-2 infection. Before being infected with SARS-CoV-2, our patients had cardiovascular morbidities (mild mitral regurgitation in one patient, ischemic heart disease with bifascicular block in the other patient) in adjunct to cardiovascular risk factors, but the SARS-CoV-2 infection contributed to quickly and significantly decompensate their balance. CONCLUSION: These findings warn that patients affected by LMNA p.R349W mutation and likely other LMNA mutations associated with cardiovascular morbidity should be considered at extremely elevated risk of post-acute cardiological manifestations and should therefore undergo a vigilant follow-up after SARS-CoV-2 infection. Both patients developed COVID-19 before the specific vaccination was available to them and this unfortunate situation should remark the importance of vaccination coverage against SARS-CoV-2 infection for all patients affected by lipodystrophy, especially those with underlying comorbidities.
format Online
Article
Text
id pubmed-8984660
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-89846602022-04-06 Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation Ceccarini, G. Gilio, D. Magno, S. Pelosini, C. Leverone, M. Miceli, C. Barison, A. Fabiani, I. Emdin, M. Santini, F. J Endocrinol Invest Original Article PURPOSE: SARS-CoV-2 infection may cause varying degrees of cardiac injury and the presence of underlying cardiovascular morbidities contributes to the frequency and severity of occurrence of this complication. Lipodystrophy syndromes are frequently characterized by severe metabolic derangements that represent relevant cardiovascular risk factors. Besides causing lipodystrophy, mutations in the lamin A/C (LMNA) gene can lead to a wide spectrum of tissue-specific disorders including cardiac involvement. METHODS AND RESULTS: We herein examine the case of two patients affected by atypical progeroid syndrome and partial lipodystrophy due to a heterozygous missense LMNA mutation c.1045 C > T (p.R349W) who presented initially with mild COVID-19 and developed severe cardiovascular complications within few weeks of SARS-CoV-2 infection. Before being infected with SARS-CoV-2, our patients had cardiovascular morbidities (mild mitral regurgitation in one patient, ischemic heart disease with bifascicular block in the other patient) in adjunct to cardiovascular risk factors, but the SARS-CoV-2 infection contributed to quickly and significantly decompensate their balance. CONCLUSION: These findings warn that patients affected by LMNA p.R349W mutation and likely other LMNA mutations associated with cardiovascular morbidity should be considered at extremely elevated risk of post-acute cardiological manifestations and should therefore undergo a vigilant follow-up after SARS-CoV-2 infection. Both patients developed COVID-19 before the specific vaccination was available to them and this unfortunate situation should remark the importance of vaccination coverage against SARS-CoV-2 infection for all patients affected by lipodystrophy, especially those with underlying comorbidities. Springer International Publishing 2022-04-06 2022 /pmc/articles/PMC8984660/ /pubmed/35384599 http://dx.doi.org/10.1007/s40618-022-01795-6 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Ceccarini, G.
Gilio, D.
Magno, S.
Pelosini, C.
Leverone, M.
Miceli, C.
Barison, A.
Fabiani, I.
Emdin, M.
Santini, F.
Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
title Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
title_full Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
title_fullStr Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
title_full_unstemmed Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
title_short Post-acute cardiac complications following SARS-CoV-2 infection in partial lipodystrophy due to LMNA gene p.R349W mutation
title_sort post-acute cardiac complications following sars-cov-2 infection in partial lipodystrophy due to lmna gene p.r349w mutation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984660/
https://www.ncbi.nlm.nih.gov/pubmed/35384599
http://dx.doi.org/10.1007/s40618-022-01795-6
work_keys_str_mv AT ceccarinig postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT giliod postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT magnos postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT pelosinic postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT leveronem postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT micelic postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT barisona postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT fabianii postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT emdinm postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation
AT santinif postacutecardiaccomplicationsfollowingsarscov2infectioninpartiallipodystrophyduetolmnagenepr349wmutation